Related Experiment Video

Updated: Apr 14, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.4K

Treating to target in axial spondyloarthritis: defining the target and the arrow

Daniel Wendling1

  • 1Department of Rheumatology, CHRU de Besançon, University Teaching Hospital, and Université de Franche-Comté, Boulevard Fleming, F-25030, Besançon, France.

Expert Review of Clinical Immunology
|April 24, 2015
PubMed

Insights

The treat-to-target strategy for axial spondyloarthritis needs clear remission definitions. New therapies targeting IL-23 and IL-17 offer improved treatment possibilities.

Area of Science:

  • Rheumatology
  • Immunology

Background:

  • The treat-to-target (T2T) concept is proposed for axial spondyloarthritis (axSpA).
  • T2T aims to achieve and maintain disease remission in axSpA patients.

Discussion:

  • Consensus definitions for remission and flare in axSpA are currently lacking.
  • These definitions are crucial for validating the T2T strategy and the window of opportunity hypothesis.

Key Insights:

  • Lack of standardized definitions hinders the validation of T2T in axSpA.
  • Emerging biologic targets like IL-23 and IL-17 are expanding therapeutic options.

Outlook:

  • Further research is needed to establish clear remission and flare criteria for axSpA.
  • Advancements in targeted therapies promise more effective management of axial spondyloarthritis.
Keywords:
IL 17IL 23ankylosing spondylitisremissionspondyloarthritistreatment

More Related Videos

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.1K
Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain07:19

Author Spotlight: Fu's Subcutaneous Needling for Knee Osteoarthritis Pain

Published on: March 24, 2023

6.4K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
804
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
989